About ImmunoGen
ImmunoGen is a company based in Waltham (United States) founded in 1981 was acquired by AbbVie in November 2023. ImmunoGen has raised $126 million across 5 funding rounds from investors including AbbVie. The company has 106 employees. ImmunoGen operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Waltham, United States
- Employees 106
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website immunogen.com
- Social LinkedIn X
- Acquired by AbbVie (Nov 2023)
Funding Insights of ImmunoGen
ImmunoGen has successfully raised a total of $126M across 5 strategic funding rounds. The most recent funding activity was a Private Equity Round of $100 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $126M
- Total Rounds 5
- Last Round Private Equity Round β $100M
- First Round $2M
(Jun 2011)
All 5 funding rounds of ImmunoGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $100M | Private Equity Round | β | β | β |
| Dec 2011 | $20M | Private Equity Round | β | β | β |
| Nov 2011 | $1M | Angel Round | β | β | β |
| Oct 2011 | $3M | Private Equity Round | β | β | β |
| Jun 2011 | $2M | Private Equity Round | β | β | β |
1 investors in total: 1 institutional.
Investors in ImmunoGen
ImmunoGen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include AbbVie.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | abbvie.com | Chicago, United States |
Investor details for ImmunoGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ImmunoGen
65 people are tracked at ImmunoGen (37 in leadership, 4 in board & advisors, 24 in team); the tracked headcount is 106.
| Name | Role | Group |
|---|---|---|
Mark Enyedy | CEO & President | Leadership |
Theresa Wingrove | Senior Vice President Of Regulatory Affairs And Quality | Leadership |
Celina Griffin | Senior Director Pharmacovigilance Science | Leadership |
Nicole Powers | Senior Director, Finance And Accounting | Leadership |
Barry Robins | Director, Product Quality | Leadership |
Jessica Young | Associate Director Strategic Account Manager | Leadership |
Carol Moore | Director, Oncology Market Access | Leadership |
Kristen Harrington-Smith | SVP & Chief Commercial Officer | Leadership |
Pattie Skeens | Head, Gcp/glp Quality Assurance | Leadership |
Ricardo Viana | Vp, Market Access EMEA | Leadership |
Stacy Coen | SVP & Chief Business Officer | Leadership |
Adrian Noë | Executive Director, Medical Information | Leadership |
Adam Dasilva | Director, Clinical Outsourcing And Contracts | Leadership |
Kathy Hawes | Director, Regulatory Operations | Leadership |
Rheyan Cader | Executive Director, Lead HR Buisness Partner | Leadership |
Francisco Ribeiro Filho | Vp, Chief Compliance Officer | Leadership |
Angelika Bekbulatova | Medical Director, Pharmacovigilance | Leadership |
Callum Sloss | Senior Director, Translational Sciences | Leadership |
James Stec | Global Executive Director Medical Affairs | Leadership |
Fabrizio Papa | Head Of Marketing Europe | Leadership |
45 more people are available in the full profile.
Complete people profiles for ImmunoGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ImmunoGen
5 dated milestones of ImmunoGen across 42 years, from founding to its latest funding, stage changes and deals.
- Founded ImmunoGen is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Private Equity Round, of $100.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by AbbVie.
Competitors of ImmunoGen
ImmunoGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. |
Detailed competitors of ImmunoGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ImmunoGen
Websites that share an audience with ImmunoGen (immunogen.com).
Websites whose visitors overlap most with ImmunoGen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| seattlegenetics.com | 100% | – | – | View details | |
healcorp.net | healcorp.net | 100% | – | – | β |
| osip.com | 99% | – | – | View details | |
| onyx-pharm.com | 97% | – | – | View details | |
| ariad.com | 94% | – | – | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 26 similar websites and full traffic analytics for ImmunoGen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 26 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Immunogen
Complete news archive for ImmunoGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ImmunoGen
10 companies that operate in the same segment as ImmunoGen (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ImmunoGen
ImmunoGen was founded in 1981 and raised its 1st funding round 30 years after it was founded.
ImmunoGen is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Mark Enyedy is the current CEO of ImmunoGen.
ImmunoGen is a funded company, having raised a total of $126M across 5 funding rounds to date. The company's 1st funding round was a Private Equity Round of $2M, raised on Jun 2011.
ImmunoGen has 106 employees.
Annual revenue of ImmunoGen is $108.78M as on Dec 31, 2022.
ImmunoGen was founded in 1981 and is headquartered in Waltham, United States. Targeted anticancer therapeutics are developed using proprietary antibody-drug conjugate technology within the biotechnology sector. Operations focus on creating treatments for solid tumors, including the lead candidate Mirvetuximab Soravtansine for folate receptor Ξ±-positive ovarian cancers. The technology is incorporated into Roches Kadcyla for HER2-positive metastatic breast cancer and is licensed to various healthcare companies for further applications.
ImmunoGen's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Syndax.
ImmunoGen has 1 investor. Key investors include AbbVie.
Yes. ImmunoGen was acquired by AbbVie in November 2023.